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prescription, and information identifying both the patient and
the prescribing optometrist or physician; and prohibits the
filling of expired prescriptions except when the patient's spec
tacles are damaged, broken, or lost. Under section 2559.6, it
is unprofessional conduct to dispense spectacle lenses on or
after January 1, 1999 for prescriptions that fail to meet the
requirements of section 2541. 1. This bill was signed by the
Governor on March 16 (Chapter 8, Statutes of 1998).
AB 2721 (Miller), as amended August 10, establishes a
four-year term of office, expiring on June 1, for members of
the Board of Optometry. This bill also provides that any Board
licensee who engages in, or aids and abets, prostitution-re
lated offenses in the workplace is guilty of unprofessional
conduct and subject to disciplinary action and fines up to
$5,000. This bill was approved by the Governor on Septem
ber 29 (Chapter 97 1 , Statutes of 1998).

Recent Meetings

At its November 14 meeting, the Board reelected Steven
S. Grant, OD, as President and Gerald J. Easton, OD, as Vice
President. Dr. John Anthony was elected Secretary, replacing
Patricia L. Gee, EdD, in this position. Reappointed Board mem
bers Dr. Sheilah Titus and Dr. Patricia Gee were also sworn in.
Also at the November meeting, Dr. Grant reported on
the progress of the 1998 occupational analysis study. An oc
cupational analysis is designed to capture information with
respect to the major tasks optometrists perform in their pro
fessional work. [ 14: I CRLR 71 J Information on the knowl
edge, skills, and abilities required of licensed optometrists in
order to perform these tasks competently will be collected
and used to evaluate the Board's current licensing examina
tion for appropriateness of test parameters and criteria. Of
2,000 surveys mailed to selected optometrists in September
1 998, 578 have been returned and submitted to R & D Data
Corporation for tabulation and interpretation. DCA's Office

of Examination Resources is satisfied with both the numbers
and demographic distribution of the surveys returned. The
final report should be completed by early 1999. The results
will not be ready by the next scheduled licensure exam (Janu
ary 11, 1999 in Sacramento) but will be reflected in ques
tions on the June 29, 1 999 examination.
SB 668 (Polanco) (Chapter 13, Statutes of 1 996) autho
rizes the Board to certify optometrists who are qualified to
use specific classes of therapeutic pharmaceutical agents
(TPA) for a limited number of eye conditions, upon comple
tion of specified education, training, and examination. Sec
tion 1568 of the CCR, adopted by the Board in 1997 to imple
ment SB 668, requires that applicants for TPA certification
complete a Board-approved, 80-hour didactic course and
specifies the University of California at Berkeley (UCB) and
the University of Southern California (USC) as institutions
where such a course will be offered. The Board has been work
ing with UCB and USC to develop the TPA course.
In November, the Board voted to approve a proposed
TPA course which will be offered by UCB. The course will
combine 60--65 hours of Internet and distance learning with
15-20 hours of onsite, hands-on training at Berkeley. The
course is being subsidized by Vision Service Plan (VSP), a
national managed care provider of vision services, in a joint
effort with UCB to reduce the financial hardships and acces
sibility problems that have made it difficult for optometrists
to obtain TPA certification. Terry Dougherty of VSP com
mented that such a course will help VSP reach its goal of
requiring that all VSP providers are TPA-certified.

Future Meetings

• March 1 4- 1 5, 1 999 in Fullerton.
• May 1 6- 1 7, 1 999 in San Jose.
• August 20-2 1 , 1 999 in Sacramento.
• November 1 4- 1 5, 1 999 in San Diego.

Board of Pharmacy

Executive Officer: Patricia Harris ♦ (916) 445-5014 ♦ Internet: www.dca.ca.gov/pharmacy/

P

ursuant to Business and Professions Code section 4000
et seq., the Board of Pharmacy grants licenses and per
mits to pharmacists, pharmacy interns, pharmacy tech
nicians, pharmacies, pharmacy corporations, nonresident
pharmacies, wholesale drug facilities, medical device retail
ers, veterinary food-animal drug retailers, out-of-state dis
tributors, clinics, and hypodermic needle and syringe distribu
tors. It regulates all sales of dangerous drugs, controlled sub
stances, and poisons. The Board is authorized to adopt regu
lations, which are codified in Division 17, Title 16 of the
California Code of Regulations (CCR).
To enforce the Pharmacy Law and its regulations, the Board
employs full-time inspectors who investigate complaints re
ceived by the Board. Investigations may be conducted openly
or covertly as the situation demands. The Board conducts fact
finding and disciplinary hearings, and is authorized by law to

suspend or revoke licenses or per
mits for a variety of reasons, includ
ing professional misconduct and any
misconduct substantially related to the practice of pharmacy.
The Board of Pharmacy is a consumer protection agency
located within the Department of Consumer Affairs (DCA).
The Board, which meets five times per year, consists of eleven
members, four of whom are nonlicensees. The remaining mem
bers are pharmacists, five of whom must be active practitio
ners. All Board members are appointed for four-year terms.

Maj or Proj ects

Data Collection Portion of CURES
Pilot Project Commences

For many years, the Board of Pharmacy has been involved
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24; the Office of Administrative Law (OAL) approved the
in a multi-agency project to automate the current paper-based
regulation
on August 27. Section 1 7 15.5 requires a dispens
"triplicate system" used when a physician or other authorized
ing
pharmacy
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prescriber prescribes, and a pharmacist dispenses, Schedule
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pharmacy for each prescription of a Schedule
II controlled substances. [ 15:4 CRLR 116; 15:2&3 CRLR 89;
II
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prescribe Schedule II narcotics on
·
ignates
the Board of Pharmacy to
a state-issued triplicate form. The -- -- -- - - ·
select
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location for submission
prescriber retains one copy and
For m any years, the Board of Pharmacy
of the information; establishes the
gives the remaining two copies to
has been involved in a multi-agency project
timeframe for submitting infor
the patient. To have the prescrip
to automate the current paper-based
mation; provides an alternate
tion filled, the patient takes the re
"triplicate system" used when a physician
method of submission and thresh
maining two parts of the form to
or other authorized prescriber prescribes,
old reporting requirements for
a pharmacy. The pharmacy en
and a pharmacist dispenses, Schedule II
pharmacies without electronic redorses the prescription, retains a
controlled substances.
porting capability; specifies the
duplicate, and checks the form for
reporting requirements for par
compliance with Health and
tially filled or dispensed prescriptions; sets the compliance
Safety Code section 11206. Section 11164 of the Health and
date for submission of information; and provides for a one
Safety Code requires the pharmacy to transmit the original of
time $75 reduction in the next license renewal fee for phar
the triplicate form to the Department of Justice's Triplicate
macies that comply with section 1715.5 by September 8, 1998.
Prescription Program at the end of the month in which the
The Board has contracted with Atlantic Associates, Inc.
prescription was filled.
in Manchester, New Hampshire to collect all the informa
The purpose of the triplicate system is to monitor closely
tion, and has sent several notices (with a CURES handbook)
the prescribing and dispensing of Schedule II controlled sub
to all California pharmacies about the new reporting require
stances to control effectively the abuse and diversion of these
ments. The Board warned pharmacies that the CURES project
narcotics while allowing patient access to appropriate medi
is operating concurrently with the existing triplicate prescrip
cations. Prescription drug diversion is the illicit distribution,
tion program; thus, pharmacies are still required to mail origi
prescribing, dispensing, or use of controlled substances that
nal triplicate prescription forms to the Department of Justice
are manufactured and intended for legitimate purposes. Drug
at the end of each month.
diversion can occur at many points in the drug distribution
chain, beginning with the manufacturer and ending with the
The Board and the Department must submit a progress
report on the data collection project to the legislature by Janu
patient or consumer. Much prescription drug diversion oc
curs at the prescribing, dispensing, or patient level, which is
ary 1, 1999. W hen the pilot project is completed in June 2000,
predominantly the focus of the triplicate system. However,
the legislature will determine the need for continuation of the
current triplicate program.
prescribers and dispensers complain that the paper-intensive
triplicate system is burdensome in light of modern electronic
Licensing Limited Liability Companies
recordkeeping methods.
At its October meeting, the Board's Licensing Commit
AB 3042 (Takasugi) (Chapter 738, Statutes of 1996)
tee discussed an emerging legal issue concerning the licen
added section 11165 to the Health and Safety Code, which
sure of a limited liability company (LLC) as a pharmacy. An
requires the Board of Pharmacy and the Department of Jus
LLC is a form of business enterprise established in 1994 by
tice to establish the Controlled Substance Utilization Review
the Beverly-Killea Limited Liability Company Act, Corpo
and Evaluation System (CURES) to electronically monitor
rations Code section 11000 et seq. [ 14:4 CRLR 120JThe LLC
the prescribing and dispensing of Schedule II controlled sub
structure offers business owners the limited liability of a cor
stances by all practitioners authorized to prescribe or dispense
poration and the pass-through tax advantages of a partner
them, "contingent upon the availability of adequate funds."
ship. An uncodified provision of the Beverly- Killea Act pro
In the meantime, AB 3042 requires that CURES be imple
hibits an LLC from rendering "professional services." Ac
mented as a three-year pilot project commencing on July 1,
cording to a March 1998 legal opinion by DCA attorney Chris
1997, to be administered concurrently with the existing trip
topher Grossgart, it is generally accepted that the uncodified
licate system, to examine the comparative efficiencies be
language prevents DCA and its constituent licensing agen
tween the two systems. Thus, the statute requires the Depart
cies from issuing "professional" licenses to an LLC; for ex
ment of Justice and Board of Pharmacy to engage in a major
ample, an LLC is precluded from holding a license to prac
data collection process to determine the relative efficiencies
tice as a pharmacist, a dentist, or a physician.
of the existing triplicate system and the electronic mainte
A more controversial question has been whether the
nance of Schedule II narcotics data.
uncodified language also prevents a DCA agency from issuing
To facilitate the collection of the required data, the Board
a permit to an LLC to operate a business in which professional
adopted section 1715.5, Title 16 of the CCR, on April 10,
services are rendered, and in fact dozens of LLCs have sub
1998 as an emergency regulation. Thereafter, it published
mitted applications to the Board for pharmacy, medical device
notice of its intent to permanently adopt the section on April
70
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(e.g., anything of value, including supplies and drugs) in or
retailer, and wholesaler licenses. Based on DCA advice, the
der to induce business reimbursed by a federally funded pro
Board has interpreted the uncodified language narrowly and
gram such as Medicare, Medicaid, or CHAMPUS. Califor
has denied the issuance of these licenses to LLCs. Applicants
nia also has an anti-kickback statute at Welfare and Institu
have countered that these pennits are merely "business" licenses
tions Code section 14107.2(a). In its advisory opinion, OIG
and, as such, are not encompassed within the prohibition against
described a particular case in which a hospital provided sup
an LLC rendering "professional" services. Whether a distinc
tion can be made between "professional" and "business" li
plies without charge to municipal ambulance companies.
Because the ambulance company could influence a patient's
censes has been the subject of great dispute. The Department
choice of hospital, and because of the risk that an ambulance
of Health Services (OHS) for example, has rejected DCA's
company would use its influence to direct a patient to a hos
narrow construction of the uncodified language.
pital that provides the ambulance company with free goods,
In a subsequent October 8 memo, Grossgart recom
OIG concluded that the arrangement would likely constitute
mended that the Board consider sponsoring legislation add
ing section 4208 to the Business and Professions Code, which
prohibited remuneration under the federal anti-kickback stat
ute. In OIG's view, state law giving patients the right to de
would authorize it to issue "site" permits to an LLC to oper
termine their destination is insufficient to deter abuse where
ate as a pharmacy, medical device retailer, wholesaler, or vet
erinary medical drug retailer. As the law currently authorizes
the hospital provides remuneration, including the provision
the Board to issue "site" permits to corporations which have
of free goods, to the ambulance service.
Adopting the position of CHA, many hospitals have dis
the same liability shield as an LLC, this proposed legisla
tion-in Grossgart's view-would not adversely affect con
continued the practice of restocking ambulances. This is not a
sumer protection.
problem for general supplies, but concerns have arisen about
At the full Board's October 28 meeting, member Darlene
the issue of restocking of controlled substances. Some ambu
Fujimoto expressed concern that licensure of LLCs might be
lances are purchasing, storing, and restocking medications and
unrelated to the Board's overall strategic plan and asked how
supplies. For controlled substances, they are using the license
such licensure would benefit the practice of pharmacy. Deputy
and DEA certificate of their contracted medical director. AcAttorney General Bill Marcus recording to Pharmacy Board Execu
sponded that allowing licensure to
tive Officer Patricia Harris, the
The Board has recently been asked to tadde
LLCs would decrease the Board's
Pharmacy Law does not specifi
a thorny problem regarding the restocking
exposure to litigation. He reiter
cally authorize clinics or hospital
of ambulance supplies (including drugs)by
ated that a considerable number
medical directors (or other physi
hospitals.
of LLCs have applied for licen
cians) to supply emergency ve
sure to establish pharmacies and
hicles with dangerous drugs, dan
are likely to challenge the Board when their applications are
gerous devices, or controlled substances. Any specific author
denied. Because some LLCs were granted licenses before
ity must be found elsewhere, such as federal or state law and
DCA's position on LLCs was clear, some applicants have sug
regulations governing emergency vehicles.
gested that the Board has acted arbitrarily.
On October 28, the Board voted unanimously to form a
At its October 28 meeting, the Board voted unanimously
task force with representatives from the California Society of
to refer the issue whether to seek the addition of Business and
Health Systems Pharmacists, the Department of Health Ser
Professions Code section 4208 to its Legislation and Regula
vices, and possibly the Office of Emergency Services to draft
tion Committee for study and recommendation to the Board.
legislation that would authorize the storage, dispensing, and
purchasing of dangerous drugs and devices for use by emer
Restocking ofAmbulances with
gency personnel.
Supplies and Medications
Implementation of the FDA Modernization
The Board has recently been asked to tackle a thorny
Act
of 1 997
problem regarding the restocking of ambulance supplies (in
cluding drugs) by hospitals. The Health Care Financing
On November 9, 1997, Congress passed the Food and
Administration's Office of the Inspector General (OIG) has
Drug Administration Modernization Act of 1997. The law was
released an advisory opinion which concludes that a hospital's
signed by President Clinton on November 21, 1997 and be
restocking of ambulance supplies likely violates federal anti
came effective on November 21, 1998. The FDA Moderniza
kickback law and raises several other legal problems, includ
tion Act of 1997 requires FDA and the fifty states to enter
ing antitrust, tax, pharmacy, and contract law issues, and pos
into a memorandum of understanding (MOU) regarding the
sible violation of the federal False Claims Act. Relying on
compounding of drugs. Compounding is the process by which
OIG's opinion, the California Healthcare Association (CHA)
a pharmacist combines, mixes, or alters ingredients to spe
has adopted a policy of discouraging the common practice of
cialize a medication for a patient, at the direction of a physi
hospitals restocking ambulance supplies (including drugs).
cian. Section 503A of the Act recognizes compounding as an
Federal anti-kickback law, 42 U.S.C. section 1 320aelement of the practice of pharmacy that is to be regulated by
the states, and distinguishes it from "manufacturing" which
7b(b ), sets forth penalties for individuals or entities that know
falls within the jurisdiction of the FDA. The purpose of the
ingly and willfully offer, pay, solicit, or receive remuneration
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section is "to ensure continued availability of compounded
drug products as a component of individualized therapy, while
limiting the scope of compounding so as to prevent manufac
turing under the guise of compounding." The purpose of the
MOU is to address the interstate distribution of "inordinate
amounts" of compounded drug products and a state's investi
gation of complaints regarding this distribution.
The law instructs the FDA and the National Association
of Boards of Pharmacy (NABP) to develop a standard MOU
for state boards. The goal of the MOU is to obtain state agree
ment on two issues: (1) protocols for the appropriate investi
gation of complaints relating to compounded drug products
shipped out-of-state; and (2) establishment of appropriate
restrictions on the amount of compounded drugs shipped in
interstate commerce, including "safe harbors" for pharma
cists who distribute compounded products in interstate com
merce. Pharmacies located in a state that does not sign a MOU
by the law's effective date (November 21) will be subject to
FDA's "safe harbor" provision, whereby compounded prod
ucts may not exceed 5% of the total prescription orders dis
pensed or distributed by that pharmacy. The MOU's "safe
harbor" language is intended to address circumstances in
which interstate distribution of compounded medications can
exceed 5% of the total quantity of dispensed medication.
At its October 28 meeting, the Board decided it would
take no action at the time; the Board directed the Licensing
Committee to monitor the progress of the MOU being devel
oped by the FDA and NABP.
Recycling of Nursing Home Drugs

The American Medical Association recently adopted a
policy reflecting recommendations made by its Council on
Scientific Affairs in a written report entitled Recycling ofNurs
ing Home Drugs. The report makes recommendations on ways
to reduce medication waste in long-term care facilities
(LTCFs). The report defines "medication waste" as any medi
cation that has been dispensed and paid for but not consumed
by a particular LTCF patient. Based on limited studies, the
report stated that the cost associated with unused medication
in LTCFs is 4-10% of the total costs of medications dispensed.
More than 90% of the wasted medication is due to discon
tinuation or change in medication or the death, transfer, or
hospitalization of the resident.
Based on the report, the AMA has adopted a policy con
sistent with the American Society of Consultant Pharmacists
(ASCP) to support the return and reuse of medications to the
dispensing pharmacy to reduce waste associated with unused
medications in LTCFs and to offer substantial savings to the
health care system. AMA and ASCP recommend that medi
cations be returned and reused only if (1) they are not con
trolled substances, (2) they are dispensed in tamper-evident
packaging and returned with packing intact, (3) in the profes
sional judgment of the pharmacist, the medications meet all
federal and state standards for product integrity, (4) policies
and procedures are followed for the appropriate storage and
handling of medications at the LTCF and for the transfer, re
ceipt, and security of medications returned to the dispensing
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pharmacy, (5) a system is in place to track restocking and
reuse to allow medications to be recalled if required, and (6)
a mechanism (reasonable for both the payer and the dispens
ing LTCF pharmacy) is in place for billing only the number
of doses used or crediting the number of doses returned, re
gardless of payer source.
On October 28, the Board unanimously voted to adopt
the Licensing Committee's recommendation that the Board
participate as a member of a task force with interested parties
to address the issue of recycling nursing home drugs.

Acceptable Remedial Pharmacy Coursework

SB 1349 (Committee on Business and Professions) (Chap
ter 549, Statutes of 1997) added section 4200. 1 to the Business
and Professions Code; effective July 1, 1998, this provision
requires candidates who have failed the Board's licensure ex
amination after four attempts to complete 16 semester units or
the equivalent of pharmacy coursework approved by the Board
as a condition of eligibility for reexamination.
In April 1998, the Board published notice of its intent to
adopt section 1725, Title 16 of the CCR, to specify the crite
ria for acceptable remedial pharmacy coursework. Under sec
tion 1725, coursework that meets the requirements of section
4200. 1 of the Business and Professions Code is any phar
macy coursework offered by a pharmacy school approved by
the American Council on Pharmaceutical Education or rec
ognized by the Board. A final examination must be part of
the course of study. W hen a candidate applies for reexamina
tion after four failed attempts, he/she must furnish evidence
of successful completion of at least 16 semester units or the
equivalent of remedial pharmacy coursework; evidence of
successful completion must be posted on a transcript from
the pharmacy school sent directly to the Board. Following a
45-day public comment period, the Board adopted section
1725; OAL approved the regulation on October 5, and it be
came effective on November 4.
Practical Training for Pharmacy Technician Trainees

Business and Professions Code section 4115 establishes
the pharmacy technician category, and directs the Board to adopt
regulations specifying that tasks which may be performed by a
pharmacy technician under the direct supervision of a licensed
pharmacist; section 1793.2, Title 16 of the CCR, specifies those
tasks. Business and Professions Code section 4202 requires
the Board to adopt regulations setting forth the qualifications
for registration as a pharmacy technician, and the required con
tents of acceptable pharmacy technician training courses. Sec
tion 1793.4, Title 16 of the CCR, sets forth the qualifications
for pharmacy technician registration; under section 1793.4(d),
one method of qualification is to work for at least one year
performing the tasks specified in section 1793.2 while employed
or utilized as a pharmacy technician, assisting in the prepara
tion of prescriptions for an inpatient of a hospital or for an
inmate of a correctional facility. Section 1793.6, Title 16 of the
CCR, specifies a three different methods of qualifying for phar
macy technician registration, and the types of knowledge which
an acceptable training program should impart to a registration

California Regulatory Law Reporter ♦ Volume 16, No. I (Winter 1999)

H E A LT H CARE RE G UL ATORY A G EN C I ES

candidate. One of the approved types of training programs
places a pharmacy technician trainee in a pharmacy to perform
the functions of a pharmacy technician under the direct super
vision and control of a licensed pharmacist.
Effective July 1 , 1 997, SB 1 553 (Kelley) (Chapter 798,
Statutes of 1996) removed an exemption from the pharmacy
technician registration requirement for persons employed or
utilized as a pharmacy technician to assist in the filling of pre
scriptions for an inpatient of a hospital or for an inmate of a
correctional facility. This amendment created "catch-22" prob
lems for the Board and for individuals then enrolled in phar
macy technician training programs, because it could be inter
preted to preclude persons serving an extemship in a pharmacy,
and attempting to qualify for pharmacy technician registration
under section l 793.4(d), from obtaining the required training.
In early 1998, the Board drafted legislation to fix the
problem created by SB 1 553; the language was ultimately
amended into SB 2239 (Committee on Business and Profes
sions), which was passed by the legislature and becomes ef
fective on January 1, 1 999 (see LEGISLATION). In the mean
time, the Board amended section 1 793.6, Title 16 of the CCR,
on an emergency basis in August 1 997, and then readopted
the emergency amendments on several occasions throughout
1998. Under the amendments, a current enrollee of a
pharmacy technician training course that meets the require
ments of section 1793.6 may obtain all or part of his/her prac
tical instruction as an enrollee of that course in a pharmacy;
such an enrollee must wear a badge that clearly identifies him/
her as a "pharmacy technician trainee." The amendments fur
ther state that the tasks performed by the trainee must be lim
ited to the ta�ks described in section 1793.2, and require that
the tasks be performed in compliance with state and federal
laws and with verification and documentation by a licensed
pharmacist as required by subsections l 793.7(a) and (b).
SB 2239 has now fixed this problem by adding section
41 15.5 to the Business and Professions Code, which clarifies
that, notwithstanding any other provision of law, a pharmacy
technician student may be placed in a pharmacy as a phar
macy technician trainee to complete an externship for the
purpose of obtaining practical training that is required by the
Board as a condition of becoming registered as a pharmacy
technician. The new statute also sets forth standards for the
supervision of pharmacy technician trainees serving in
externships in pharmacies.
Board PrOf)oses to Reduce License Renewal Fees

Sections 1 749 . 1 and 1 793.5, Title 16 of the CCR, set forth
various fees and penalties charged by the Board for licenses,
permits, registrations, and other services. Business and Pro
fessions Code section 4400(s) directs the Board to maintain a
reserve fund equal to approximately one year's expenditures.
In the early 1990s, to help offset a large budget deficit in
the state's general fund, the state's Budget Act permitted the
director of the Department of Finance to remove any surplus
exceeding three months of operating expenses from any spe
cial fund agency. [12:4 CRLR 1J In the case of the Board of
Pharmacy, $5.4 million was transferred from the Board's

reserve fund to the general fund. This transfer made it difficult
for the Board to meet operational expenses with respect to its
enforcement and consumer awareness programs. To help meet
its expenses, the Board sought a fee increase, which was granted
and became effective on July 1 , 1995. [15:2&3 CRLR 90]
On behalf of the licensees of a number of occupational
agencies whose reserve funds were raided by the state, Los
Angeles attorney Richard Fine sued the state to compel reim
bursement of the removed funds. [15:4 CRLR 39-40] The
state recently settled the lead case, Malibu Video Systems, et
al. v. Kathleen Brown, et al., No. BC082830 (Los Angeles
County Superior Court), and agreed to refund the monies to
the agencies over a multi-year period. In fiscal year 199899, the Board of Pharmacy was reimbursed $3,798,197 of
the $5.4 million transferred to the general fund in fiscal year
1991-92. The Board anticipates the return of an additional
$ 1 , 1 38,990 during fiscal year 1 999-2000. Based upon pro
jected revenues and expenditures, the Board will end fiscal
year 1 999-2000 with a reserve of 19.6 months' worth of op
erational expenditures; it will have 1 8.9 months by fiscal year
2000-2001 , and 17.9 months by fiscal year 2001-2002.
In light of this recovery, the Board published notice on
November 27 of its intent to reduce its pharmacist and phar
macy renewal fees in order to slow the accrual of funds and
achieve a fund level consistent with approximately one year's
operating expenses. The Board has determined that the pro
posed regulatory action would reduce its reserve fund to a
level of 1 6.6 months by fiscal year 1 999-2000, 1 3.0 months
by fiscal year 2000-200 1 , and 9.2 months by 2001-2002. The
fund level achieved by 2001-2002 would be consistent with
the provisions of Business and Professions Code section
4400(s), and would be considered prudent by DCA and the
Department of Finance.
Under the Board's proposed amendments, its pharma
cist biennial renewal fee would be $ 1 15, and its annual phar
macy renewal fee would be $175, effective July 1 , 1999. At
this writing, the Board does not plan to hold a public hearing
on the proposed amendments, but is accepting written com
ments until January 1 1 , 1999.

Legislation

SB 2239 (Committee on Business and Professions), as
amended August 24, enacts various technical changes affect
ing licensing boards within DCA; several of the bill's provi
sions affect the Board of Pharmacy.
As noted above, SB 2239 adds section 41 15.5 to the Busi
ness and Professions Code, concerning pharmacy technician
trainee externships (see MAJOR PROJECTS). This provision
expressly authorizes any pharmacy technician student (defined
as a person enrolled in a pharmacy technician training pro
gram operated by a California public postsecondary educa
tion institution or by a private postsecondary vocational insti
tution approved by the Bureau for Private Postsecondary and
Vocational Education) to be placed in a pharmacy as a phar
macy technician trainee to complete an externship for the pur
pose of obtaining practical training that is required by the Board
as a condition of becoming registered as a pharmacy techni-
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ciao. The new provision also states that a pharmacy techni
cian trainee participating in such an externship may perform
pharmacy technician duties only under the immediate and
personal supervision and control of a pharmacist who is on
the premises and has the trainee within his/her view at any
time the trainee performs such duties. The pharmacist is di
rectly responsible for the conduct of the trainee, and must verify
any prescription prepared by the trainee by initialing the pre
scription label before the medication is disbursed to a patient.
No more than one pharmacy technician trainee per pharma
cist may participate in an externship. An externship may last
up to 120 hours; however, if the extemship involves a rotation
between a community and hospital pharmacy for the purpose
of training the student in distinct practice settings, it may last
for 320 hours. At all times while on the job, the trainee must
wear identification that indicates his/her student status.
SB 2239 also amends section 4301 of the Business and
Professions Code to restore cash compromise as unprofes
sional conduct and grounds for disciplinary action. Last year's
SB 1349 repealed this subsection since the Board's prosecu
tors had not used it in years. However, as SB 1349 was near
ing enrollment, a cash compromise case appeared. SB 2239
restores section 4301(m) to define the cash compromise of a
charge of violation of Chapter 13 (commencing with Section
801) of Title 21 of the United States Code regulating controlled
substances as unprofessional conduct; the record of the com
promise is conclusive evidence of unprofessional conduct.
SB 2239 adds section 4301.5 to the Business and Profes
sions Code to provide that if a California-licensed pharma
cist is also licensed in another state or jurisdiction, and that
other state or jurisdiction suspends or revokes that license,
the pharmacist's California license shall be suspended auto
matically for the duration of the other state's suspension or
revocation. The Board must notify the pharmacist regarding
the status of his/her California license and of his/her right to
have the issue of penalty heard under a new expedited proce
dure established in this section.
SB 2239 also amends section 4322 of the Business and
Professions Code to impose substantially higher civil penal
ties and fines on a person who attempts to secure or secures
licensure for him/herself or another person by making false
representations, or who fraudulently represents him/herself
to be licensed. This offense is punishable as a misdemeanor;
upon conviction, a fine of $5,000 (increased from $400) and
imprisonment of 50 days could be imposed.
The bill also amends Health and Safety Code section
11166 to permit pharmacists to fill prescriptions for Sched
ule II drugs within 14 days after the triplicate was written;
existing law prohibits dispensing if the prescription is "ten
dered" to the pharmacist seven days after it is issued.
Finally, SB 2239 repeals and reenacts Health and Safety
Code section 11167 to extend from 72 hours to seven days
the period within which a prescriber's emergency oral order
for a Schedule II drug must be followed by the triplicate pre
scription. This bill was signed by the Governor on Septem
ber 26 (Chapter 878, Statutes of 1998).
SB 440 (Maddy). Under existing law, a pharmacist may
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perform certain procedures or functions as part of the care
provided by a health care facility, a licensed clinic, or a pro
vider under contract with a health plan, in accordance with
policies, procedures, or protocols of that facility, licensed
clinic, or health plan. As amended June 25, SB 440 permits a
pharmacist to also perform procedures and functions as part
of the care provided by a home health agency licensed by the
state Department of Health Services . A pharmacist perform
ing any of these procedures for a licensed home health agency
must perform the procedures in accordance with a written,
patient-specific protocol approved by the treating or super
vising physician; any change, adjustment, or modification of
an approved preexisting treatment or drug therapy must be
provided in writing to the treating or supervising physician
within 24 hours . This bill was signed by the Governor on
August 21 (Chapter 347, Statutes of 1998).
SB 625 (Rosenthal), as amended April 23, requires health
plans that provide prescription drug benefits and maintain one
or more drug formularies to provide to members of the pub
lic, upon request, a copy of the current list of prescription
drugs on the formulary by major therapeutic category; and to
maintain an expeditious process by which prescribing pro
viders may obtain authorization for a medically necessary
nonformulary prescription drug. This bill was signed by the
Governor on June 19 (Chapter 69, Statutes of 1998).
AB 974 (Gallegos), as amended June 3, prohibits health
plan contracts covering prescription drug benefits that are is
sued, amended, or renewed on or after July 1, 1999 from lim
iting or excluding coverage for a drug for an enrollee if the
drug previously had been approved for coverage by the plan
for a medical condition of the enrollee and the plan's pre
scribing provider continues to prescribe the drug for the medi
cal condition, provided that it is appropriately prescribed and
is considered safe and effective for treatment. This bill does
not preclude the prescribing provider from prescribing an
other drug that is covered by the plan and is medically appro
priate, nor does it prohibit generic drug substitutions pursu
ant to specified existing law. AB 974 also requires every health
plan that covers prescription drug benefits to comply with
certain notice requirements with respect to whether the plan
uses a formulary and to provide certain information about
drugs on the formulary to the public, upon request. Under
AB 974, plans that use a formulary must provide an enrollee
or member of the public, upon request, with a list of all of the
drugs contained in the plan's formulary, and provide infor
mation, by telephone, about whether specific drugs are on
the plan's formulary. This bill was signed by the Governor on
June 19 (Chapter 68, Statutes of 1998).
SB 1606 (Lewis), as amended August 24, provides that,
commencing July 1, 1999, limitations imposed on the num
ber or quantity of oral or suppository form drugs provided by
a pharmacy to a skilled nursing or intermediate care facility
shall not apply to an automated drug delivery system, when a
pharmacist controls access to the drugs. [ 15:4 CRLR 11718] The bill also provides that, commencing July 1, 1999,
access to an automated drug delivery system shall be limited
to personnel authorized by law to administer drugs and who
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prescription must also indicate that the prescriber has certihave an access code to the system; sets forth requirements of
a health facility and pharmacy with regard to the installation,
fled that the patient is terminally ill by the words " 1 1 159.2
exemption." The bill further authorizes a pharmacist to fill
operation, and review of an automated drug delivery system;
such a prescription when there is a technical error in the cerand exempts an automated drug delivery system from certain
tification, provided that he/she has personal knowledge of
Iabeling requirements. This bill was signed by the Governor
the patient's terminal illness, and subsequently returns the
on September 22 (Chapter 778, Statutes of 1998).
prescription to the prescriber for correction within 72 hours.
AB 1889 (Knox), as amended August 25, would have
The bill defines "terminally ill" as a patient who, in the
required the Board of Pharmacy to conduct a study of
reasonable medical j udgment of the prescribing physician,
medication error rates and negative drug interaction, using
has been determined to be suffering from an illness that is
$300,000 from the Board's Contingent Fund. The Governor
incurable and irreversible; whose illness, in the reasonable
vetoed the bill on September 27. In his veto message, the
medical judgment of the prescribing physician, will, if the
Governor stated that the methodology of the study was
illness takes its normal course, bring about the death of the
wrongly conceived and that the study was potentially unnecpatient within a period of one year; and whose treatment by
essary because current pending studies could provide the same
the physician prescribing a Schedule II controlled substance
information sought by the proposed study.
is primarily for the control of pain, symptom management,
AB 2687 (Gallegos), as amended August 28, authorizes
or both, rather than for cure of the illness.
a local health officer who determines that a person within
The Board opposed AB 2693 for several reasons. First,
his/herjurisdiction is unlawfully dispensing or furnishing danasserted that some patients would learn that the
Board
the
gerous drugs or devices to take action to stop such sales, inexemption" means they have a terminal ill59.2
1
1
1
"
term
eluding receiving and investigating complaints from the pubundermine attempts to keep terminal diwould
which
ness,
lic, other licensees, or health care facilities; issuing an order
Second, the bill obligates the pharmapatients.
from
agnoses
to the person to immediately cease and desist from the unis terminally ill to be exempt from
patient
the
assure
to
cist
lawful activity; and ordering the closure of the business oprequiring the pharmacist to conprescription,
triplicate
the
erated, managed, or owned by that person. The bill also auThird, the Board fears that
verification.
for
prescriber
the
tact
thorizes a local health officer to order the immediate closure
of Schedule II drugs by
diversion
drug
facilitate
will
bill
the
of a business upon reasonable suspicion that the business poses
and account for
dispense,
prescribe,
to
way
another
creating
an immediate threat to public health, welfare, or safety. The
of Schedule II
dispensing
the
bill requires that any person whose
··· ·-· . ----··· _ - - · _ • __ . ..
drugs
without
compliance
business is closed as a result of local
Effective January I , 1999; sect ion 1 71 5
e
with
the
system. Fitriplicat
health officer action be given notice
requi res the pharmacist-in-charge of each I
the
Board
nally,
argued
that
and a hearing to show cause why the
ph armacy to complete a self-assessm ent . 1
C
the
report
is
URES
because
closure is unwarranted. This bill
i
of thepharmacyts co mplian ce with federal
due by January 1 , 1999, this
makes it a misdemeanor for any unli- ; and state pharmacy laws.
bill is premature in its piececensed person to knowingly dispense
meal elimination of the triplior furnish a dangerous drug or dancate requirement for this category of prescription. However,
gerous device, or to knowingly own, manage, or operate a
this bill was signed by the Governor on September 23 (Chapbusiness that dispenses or furnishes a dangerous drug or danter 789, Statutes of 1998).
gerous device, when that business is not licensed to dispense
AB 2721 (Miller), as amended August 10, clarifies that
or furnish such products. Upon conviction, each violation is
Pharmacy Board members serve a term of four years, expirpunishable by imprisonment in a county jail not to exceed
ing on June 1 . The bill also provides that any Board licensee
one year, or by a fine not to exceed $5,000, or by both that
who engages in, or aids and abets, prostitution in the workfine and imprisonment. Upon a second or subsequent conplace is guilty of unprofessional conduct and is subject to
viction, each violation is punishable by imprisonment in a
disciplinary action against his/her license; the bill also procounty jail or by fine. This bill was signed by the Governor
vides for the imposition of a civil penalty in such cases. This
on September 22 (Chapter 750 of the Statutes of 1998).
bill was signed by the Governor on September 29 (Chapter
AB 2693 (Migden), as amended August 1 8 , provides that
971 , Statutes of 1998).
a prescription for a Schedule II controlled substance for use
SB 2238 (Committee on Business and Professions), as
by a patient who has a terminal illness is exempt from the
amended August 26, requires the Board of Pharmacy to initriplicate requirement; however it must comply with requiretiate the rulemaking process on or before June 30, 1999, to
ments set forth in the bill. AB 2693 requires such a prescripadopt regulations requiring its licentiates to provide notice to
tion to be signed and dated by the prescriber and to contain
clients and customers that they are licensed by the state of
the name of the person for whom the controlled substance is
prescribed, the name and quantity of the controlled substance
California. SB 2238 also requires the Board to submit to the
prescribed and directions for use, the address of the person
DCA Director, on or before December 3 1 , 1999, its method
for whom the controlled substance is prescribed, and specific
for ensuring periodic evaluation of every licensing examinainformation about the prescriber such as telephone number
tion that it administers. This bill was signed by the Governor
and federal controlled substance registration number. The
on September 28 (Chapter 879, Statutes of 1998).

California Regulatory Law Reporter ♦ Volume 16, No. 1 (Winter 1999)

75

H E A LT H C A R E R E G U L AT O RY A G E N C I E S
Recent Meetings

At its October meeting, Board staff gave a presentation to
the Board on its new "self-assessment" program under section
1715, Title 16 of the CCR. Effective January 1, 1999, section
1715 requires the pharmacist-in-charge of each pharmacy to
complete a self-assessment of the pharmacy's compliance with
federal and state pharmacy laws. The assessment must be
performed before March 31 of every odd-numbered year. The
pharmacist-in-charge must also complete a self-assessment
within 30 days whenever ( 1) a new pharmacy permit has been
issued, or (2) there is a change in the pharmacist-in-charge.
The primary purpose of the self-assessment is to pro
mote compliance with the law through self-examination and
education. The Board has developed two forms to guide a
pharmacist's self-assessment: Form 171-29 is for community
pharmacies, and Form 171-30 is for hospital inpatient phar
macies. The forms require the pharmacist-in-charge to evalu
ate the pharmacy's compliance with federal and state laws
and regulations regarding facility condition and security, drug

stock, posting of certificates and notices, pharmacist-in-charge
obligations, intern pharmacist activities, pharmacy technician
activities, general pharmacy practice, corresponding respon
sibility for filling controlled substances prescriptions, pre
scription requirements, prescription labeling and dispensing,
refill authorization, prescription transfers, confidentiality of
prescriptions, recordkeeping requirements for all dangerous
drugs, recordkeeping requirements for controlled substances,
automated dispensing devices, repackaging for use by the
pharmacy, compounding unapproved drugs for future use or
prescriber use, and electronic transmission of prescriptions.
Each self-assessment must be kept on file in the pharmacy
for three years after it is performed.

Future Meetings

• January 20-2 1 , 1 999 in Orange County.
• March 24-25, 1 999 in Sacramento.
• May 1 2- 1 3, 1 999 in San Diego.
• July 28-29, 1 999 in San Francisco.
• October 20-2 1 , 1 999 in Sacramento.

Board of Podiatric Medicine

Executive Officer: James H. Rathlesberger ♦ (916) 263-2647 ♦ Internet: www.dca.ca.gov/bpml

he Board of Podiatric Medicine (BPM) regulates the
practice of podiatry in California pursuant to Business
and Professions Code section 2460 et seq. and Article
12 of the Medical Practice Act (Business and Professions Code
section 2220 et seq.). BPM's regulations appear in Division
13.9, Title 16 of the California Code of Regulations (CCR) .
The mission of the Board of Podiatric Medicine is to
ensure the protection of consumers through proper use of the
licensing and enforcement authorities delegated to it by the
legislature. BPM is a consumer protection agency within the
Department of Consumer Affairs (DCA) and its Medical
Board of California (MBC) .
The Board licenses doctors of podiatric medicine
(DPMs), administers two licensing tests per year, approves
colleges of podiatric medicine, and enforces professional stan
dards by initiating investigations and taking disciplinary ac
tion where appropriate. The Board consists of four licensed
podiatrists and three public members.

T

Maj or Proj ects

8PM Undergoes the Sunset Review Process

During the fall of 1997, the necessity and performance of
BPM were reviewed by the Joint Legislative Sunset Review
Committee (JLSRC) and DCA under the "sunset review" pro
cess set forth in SB 2036 (McCorquodale) (Chapter 908, Stat
utes of 1994). Under the sunset process, the legislature inserts
an expiration date into the enabling act of each DCA regula
tory board; prior to that date, the JLSRC must review the need
for and performance of the board, and the legislature must pass
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a bill extending the life of the
agency or it ceases to exist. [15:4
CRLR 32] As required under the
statute, BPM submitted a lengthy
report describing its mission, func
tions, and activities on October 1 , and answered questions from
JLSRC members at a hearing on November 17, 1997.
BPM's sunset report contained some interesting and
somewhat controversial recommendations. First, BPM rec
ommended that its composition be converted from a profes
sional member majority to a public member majority. At the
time, the Board was composed of four podiatrists and two
public members. Although most non-health care occupational
licensing boards (with the exception of the Board of Accoun
tancy) are dominated by public members, only one Califor
nia health care licensing board-the Board of Vocational
Nurses and Psychiatric Technicians-consists of a public
member majority, and it only recently achieved that status
during its 1 996-97 sunset review process. BPM proposed to
become the second, with a nine-member board consisting of
five public members and four DPMs.
BPM first voted to seek a public member majority in
N ovember 1995 . [15:4 CRLR 1 04] Throughout 1996 and
1997, BPM held public hearings on its proposal to convert to
a public member majority. Strenuously opposing the proposal
at every hearing was the California Podiatric Medical Asso
ciation (CPMA). At BPM's sunset hearing, CPMA testified
that "the Board of Podiatric Medicine is fulfilling its public
protection role in an exemplary fashion with its current pro
fessional member majority." CPMA stated that it is unaware
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